ANEB
Anebulo Pharmaceuticals, Inc.NASDAQHealthcare$0.75-24.24%ClosedMarket Cap: $30.6M
As of 2026-04-04
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
3.57
P/S
0.00
EV/EBITDA
-2.30
DCF Value
$0.34
FCF Yield
-20.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-74.6%
ROA
-84.7%
ROIC
-102.7%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $0.00 | $-2.0M | $-0.05 |
| Q1 2026 | $0.00 | $-2.2M | $-0.05 |
| Q4 2025 | $0.00 | $-2.1M | $-0.05 |
| FY 2025 | $0.00 | $-8.5M | $-0.25 |
Analyst Ratings
View AllMaxim GroupHold
2025-07-23Maxim GroupBuy
2025-05-15Trading Activity
Insider Trades
View AllLawler Joseph F.director, 10 percent owner:
SellMon Apr 07
Lawler Joseph F.director, 10 percent owner:
SellMon Apr 07
SHAH BIMAL R.director
SellMon Apr 07
SHAH BIMAL R.director
SellMon Apr 07
Cundy Kenneth Cofficer: Chief Scientific Officer
SellMon Apr 07
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
-0.70
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.